Back to Authors

Downing, Nicholas S.

A5028341652 | I1283280774

Mayo Clinic

Bain Capital Life Sciences, Boston, Massachusetts

Citations 7

Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019

JAMA Network Open | June 10, 2021 | Volume: 4 | Issue: 6 | Pages: e2113224

10.1001/jamanetworkopen.2021.13224 | PMID 34110392

Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017

JAMA Network Open | April 21, 2020 | Volume: 3 | Issue: 4 | Pages: e203284

10.1001/jamanetworkopen.2020.3284 | PMID 32315070

New and incremental FDA black box warnings from 2008 to 2015

Expert Opinion on Drug Safety | December 7, 2017 | Volume: 17 | Issue: 2 | Pages: 117-123

10.1080/14740338.2018.1415323 | PMID 29215916

Characteristics of Novel Therapeutics and Postmarket Safety Events—Reply

JAMA | October 3, 2017 | Volume: 318 | Issue: 11 | Pages: 1067

10.1001/jama.2017.11517 | PMID 28975302

Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010

JAMA | May 11, 2017 | Volume: 317 | Issue: 18 | Pages: 1854

10.1001/jama.2017.5150 | PMID 28492899

Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature

JAMA Internal Medicine | May 6, 2014 | Volume: 174 | Issue: 7 | Pages: 1176

10.1001/jamainternmed.2014.1371 | PMID 24796406

Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012

JAMA | January 21, 2014 | Volume: 311 | Issue: 4 | Pages: 368

10.1001/jama.2013.282034 | PMID 24449315